A Phase 2/3 interventional study of FreeStyle Navigator Continuous Glucose Monitoring System in Diabetes Mellitus, Insulin-Dependent, sponsored by Jaeb Center for Health Research. Completed at 6 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-09-05.
Sponsored by Jaeb Center for Health Research · Phase 2/3 and Interventional
This study is being done to find out how accurate the Navigator continuous glucose monitor is in children. It is also being done to see if use of the Navigator can improve blood sugar control and help prevent low blood sugar events. This study has three basic parts: Use of the Navigator at home for one week without being able to see the blood sugar readings; a Baseline visit or a 24-hour admission to a research unit of the hospital to find out how well the Navigator measures the blood sugar; and then 3 months use of the Navigator at home as an aid to diabetes care.
Approximately 60 children will be recruited from five centers in the United States to participate in this study. The information gained from this study will be used to plan a larger study in which half of the patients will use the Navigator and half will not. Children who participate in this study will not be eligible to take part in the larger study.
The Navigator provides a glucose reading every 60 seconds (or 1440 readings a day). Each sensor is designed to provide readings for up to 120 hours. It has alarms for hypoglycemia and hyperglycemia and for projected high and low glucose values. The alarm set points can be adjusted by the user. The Navigator also has a trend arrow indicating the glucose rate of change (>-2 mg/dL/min, -2 to -1 mg/dL/min, -1 to 1 mg/dL/min, 1 to 2 mg/dl/min, and >2 mg/dl/min). Subjects can enter events, such as when they took insulin, ate, or exercised. The sensor requires calibration values to be entered 3 times during the first day of wear at 1-hour, 3-hours, and 24-hours and does not require additional calibration values. The values are entered directly into the Navigator which has a TheraSense Freestyle home glucose meter built into the unit. The Navigator has not yet been approved by the FDA. The Navigator currently under review by the FDA will limit sensor wear to 3 days.
Beginning the Study
When a child enters the study, the following will be done:
Questionnaires will be completed.
Children will be asked to do the following before returning for the Baseline Visit or the hospital stay about 1 week later:
Baseline Visit Children who are using Lantus with MDI therapy will return for a Baseline Visit approximately one week (7-12 days) after the enrollment visit.
Hospital Stay Those children who are using insulin pump therapy will return for a hospital stay approximately one week (7-12 days) after the enrollment visit and will use the Navigator for about 24 hours. The last sensor that was placed at home will continue to be worn during the hospital stay. A new sensor will also be placed so that your child has 2 sensors inserted during the hospital stay to see how closely the 2 sensors agree.
A CGMS sensor will be inserted and calibrated one hour later.
A small tube called a catheter will be placed in a vein in the child's arm and will stay in the vein while the child is in the hospital. From this tube, a very small blood sample will be drawn every 30 minutes during the hospital stay. After breakfast, blood samples will be taken about every 10 minutes for about an hour. For children who are at least 7 years old, blood samples will be taken about every 20 minutes during a period of exercise in the afternoon.
Procedures at Home after the Baseline Visit or Hospital Stay
Use the Navigator.
Study Visits
Children will return to the diabetes clinics for visits 1, 3, 7, and 13 weeks after the hospital stay. At these visits, the following will be done:
At the 3, 7, and 13- week visits, parents and children (if at least 9 years old) will be asked to complete a questionnaire about how much you liked or disliked the instructions that were given for using the results of the Navigator.
At the 7-week visit, the following will also be done in addition to the child's regular clinic visit:
At the 13-week visit, the following will also be done in addition to the child's regular clinic visit:
Questionnaires will be completed
Those who decide to continue using the Navigator will be seen again at 26-weeks.
10,925 studies on the registry are indexed under Diabetes Mellitus; 1,319 are open to participants now.
This study's enrollment of 60 is below the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Jaeb Center for Health Research is the lead sponsor of 126 studies on the registry; 17 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 14 (88%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The presence of any of the following diseases:
Feasibility of using the Navigator sensor on a daily basis (Average number of sensors used per week, Average number of hours of use per sensor, Number of sensors per week that fail to calibrate)
Navigator Accuracy
Psychosocial Questionnaires
Exploratory assessment of impact of Navigator on HbA1c
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jaeb Center for Health Research